Press releases

All types

All types

News

Press releases - Regulatory

Press releases - Non regulatory

All years

All years

2022

2021

2020

2019

2018

2017

2015

2010

2009

  • Bulletin from Annual General Meeting in Isofol Medical AB (publ) held on May 19, 2022

    Regulatory press release

    Today on May 19, 2022 in Gothenburg – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL),…

  • Isofol Medical AB (publ) publishes interim report, January–March 2022

    Regulatory press release

    GOTHENBURG, Sweden, May 12, 2022 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today…

  • Invitation to presentation of Isofol’s report for the first quarter of 2022

    Non regulatory press release

    GOTHENBURG, Sweden, May 3, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) (“Isofol”), will…

  • Isofol Medical AB (publ) publishes annual report and corporate governance report for 2021

    Regulatory press release

    GOTHENBURG, Sweden, April 27, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), today announced…

  • Isofol announces start of study data analysis of phase III AGENT study in advanced metastatic colorectal cancer

    Regulatory press release

    GOTHENBURG, Sweden, April 22, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), today announced…

  • Notice to attend the Annual General Meeting held on May 19, 2022 in Isofol Medical AB (publ)

    Regulatory press release

    GOTHENBURG, Sweden, April 12, 2022 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), hereby invites…

  • Isofol Medical AB’s (publ) Nomination Committee proposes New Chair of the Board

    Regulatory press release

    GOTHENBURG, Sweden, April 8, 2022 – The Nomination Committee of Isofol Medical AB (publ) (Nasdaq…

  • Isofol Medical AB (publ) publishes year-end report, January – December 2021

    Regulatory press release

    GOTHENBURG, Sweden, February 24, 2022 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today…

  • Invitation to presentation of Isofol’s year-end report 2021 on February 24, 2022

    Non regulatory press release

    GOTHENBURG, Sweden, February 14, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) (“Isofol”), will…

  • Isofol recognizes World Cancer Day on February 4

    News

    Today, February 4, is World Cancer Day, and we at Isofol are sending our thoughts…

  • Isofol Medical AB (publ) appoints Jenny Sundqvist as Chief Commercial Officer

    Non regulatory press release

    GOTHENBURG, Sweden, December 10, 2021 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), today announced…

  • Isofol Medical AB (publ) invites to an audiocast on December 6 at 08.00 a.m. CET

    Non regulatory press release

    GOTHENBURG, Sweden, December 5, 2021 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), announced on…

  • Isofol Medical AB (publ) will not reach 300 PFS events in the AGENT study with current censoring rules based on FDA decision

    Regulatory press release

    GOTHENBURG, Sweden, December 3, 2021 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), announced today…

  • Isofol Medical AB (publ) receives FDA Fast Track Designation for arfolitixorin in advanced colorectal cancer (mCRC)

    Regulatory press release

    GOTHENBURG, Sweden, November 23, 2021 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), announced today that…

  • Isofol appoints nomination committee ahead of the Annual General Meeting 2022

    Regulatory press release

    GOTHENBURG, Sweden, November 19, 2021 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol” or…

  • Isofol Medical AB (publ) publishes interim report for January – September 2021

    Regulatory press release

    GOTHENBURG, Sweden, November 11, 2021 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today…

  • Trading in Isofol’s shares commences today on Nasdaq Stockholm

    Regulatory press release

    GOTHENBURG, Sweden, October 21, 2021 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol” or…

  • Isofol Medical AB (publ) publishes prospectus and new financial information in connection with listing on Nasdaq Stockholm

    Regulatory press release

    GOTHENBURG, Sweden, October 18, 2021 - Isofol Medical AB (publ), (Nasdaq First North Premier Growth…

  • Isofol Medical AB (publ) intends to list its shares on Nasdaq Stockholm

    Regulatory press release

    GOTHENBURG, Sweden, October 15, 2021 - Isofol Medical AB (publ), (Nasdaq First North Premier Growth…

  • Company presentation at LSX Nordic Congress 2021

    News

    From September 7-17 Isofol participated in LSX Nordic Congress, an opportunity for 1:1 meetings with…

  • Pareto Securities´ Healthcare Conference 2021

    News

    Isofol attended Pareto Securities´ Healthcare Conference on September 1, 2021. If you missed the live…

  • Bulletin from Annual General Meeting in Isofol Medical AB (publ) held on June 23, 2021

    Regulatory press release

    Today on June 23, 2021 in Gothenburg – Isofol Medical AB (publ), (Nasdaq First North…

  • Isofol raises SEK 500 million in oversubscribed rights issue and exercised over-allotment option

    Regulatory press release

    GOTHENBURG, Sweden, June 14, 2021 - Isofol Medical AB (publ) (Nasdaq First North Premier Growth…

  • Interview with Isofol´s CEO made by Pareto Securities

    News

    See the interview with our CEO, Ulf Jungnelius, that was made by Pareto Securities, in…

  • Abstract at the upcoming ASCO meeting in June 2021

    News

    Isofol will present an abstract at the annual ASCO meeting between June 4- June 8.…

  • Isofol publishes prospectus in connection with the fully guaranteed preferential rights issue of approximately SEK 400 million

    Regulatory press release

    GOTHENBURG, Sweden, May 25, 2021 - Isofol Medical AB’s (publ), (Nasdaq First North Premier Growth…

  • Isofol’s Board of Directors resolves on a fully guaranteed preferential rights issue of approximately SEK 400 million

    Regulatory press release

    GOTHENBURG, Sweden, May 18, 2021 - Isofol Medical AB’s (publ), (Nasdaq First North Premier Growth…

  • Isofol completes recruitment of Japanese patients in the global phase III AGENT study

    Non regulatory press release

    GOTHENBURG, Sweden, May 6, 2021 – In December 2020, Isofol Medical AB (publ) (“Isofol”), (Nasdaq…

  • Isofol announces its intention to carry out a fully guaranteed preferential rights issue of approximately SEK 400 million and a potential over-allotment option of up to approximately SEK 100 million

    Regulatory press release

    GOTHENBURG, Sweden, April 28, 2021 - Isofol Medical AB (publ), (Nasdaq First North Premier Growth…

  • Interviewed made by Redeye

    News

    Redeye has interviewed Ulf Jungnelius, CEO of Isofol, regarding the announcement that the AGENT study…

  • Isofol receives notice that Clinical Use Patent in Europe for Drug Candidate arfolitixorin will be approved

    Non regulatory press release

    GOTHENBURG, Sweden, March 22, 2021 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth…

  • Invitation to a conference call and webcast in connection with Isofol receiving recommendation to complete the global Phase III AGENT study for market registration as planned with 440 patients

    Non regulatory press release

    GOTHENBURG, Sweden, March 22, 2021 - Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier…

  • Isofol receives recommendation from iDSMB to complete the global Phase III AGENT study for market registration as planned with 440 patients

    Regulatory press release

    GOTHENBURG, Sweden, March 19, 2021 - Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier…

  • The abstract for AACR 2021 has been published

    News

    The approved abstract for the congress American Association for Cancer Research (AACR) 2021 has been…

  • Isofol announces that an abstract has been approved for AACR in April 2021

    News

    Isofol announces that an abstract has been approved for presentation at the virtual American Association…

  • Isofol to present gene expression results from the completed Phase I/IIa ISO-CC-005 study today at ASCO-GI 2021 and updates of the timing of the interim analysis in the AGENT study

    News

    GOTHENBURG, Sweden, January 15, 2021 - Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier…

  • Isofol reaches 440 patients in global Phase III AGENT study

    News

    GOTHENBURG, Sweden, December 9, 2020 - Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier…

  • Isofol presents an abstract at ASCO GI in January 2021

    News

    Isofol announces that an abstract, including arfolitixorin in the ISO-CC-005 study, has been accepted to…

  • Isofol announces licensing agreement for Paladin Labs Inc. to commercialize arfolitixorin in Canada

    Regulatory press release

    GOTHENBURG, Sweden, November 2, 2020 - Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier…

  • 55 % Overall Response Rate on the safety extension cohorts of the ISO-CC-005 Phase I/IIa study

    Non regulatory press release

    GOTHENBURG, Sweden, September 30, 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth…

  • Strengthened patent protection for arfolitixorin in Japan

    Non regulatory press release

    GOTHENBURG, Sweden, September 1, 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth…

  • Invitation to a conference call and webcast by Isofol in connection with the entered license agreement with Solasia

    Non regulatory press release

    GOTHENBURG, Sweden, August 13, 2020 - Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier…

  • Isofol enters licensing agreement with Solasia to develop and commercialize arfolitixorin in Japan

    Regulatory press release

    GOTHENBURG, Sweden, August 13, 2020 - Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier…

  • Isofol’s CEO Ulf Jungnelius has subscribed for all warrants

    Non regulatory press release

    GOTHENBURG, Sweden, August 4, 2020 – Isofol Medical AB (http://isofol.se/en/) (publ) (Nasdaq First North Premier Growth…

  • A milestone is reached with the inclusion of 330 patients in the AGENT-study – opening up for the interim analysis

    Regulatory press release

    GOTHENBURG, Sweden, July 21, 2020 – Isofol Medical AB (Nasdaq First North Premier Growth Market: ISOFOL),…

  • AGENT study update with regards to COVID-19

    Non regulatory press release

    GOTHENBURG, Sweden, July 10, 2020 – Isofol Medical AB (publ) (Nasdaq First North Premier Growth…

  • Isofol’s rights issue oversubscribed

    Regulatory press release

    GOTHENBURG, Sweden, June 3, 2020 - Isofol Medical AB (publ) (Nasdaq First North Premier Growth…

  • Consortium of investors acquires subscription rights from Isofol´s founder Professor Bengt Gustavsson

    Non regulatory press release

    GOTHENBURG, Sweden, May 29, 2020 - Isofol Medical AB’s (publ) (Nasdaq First North Premier Growth…

  • Isofol publishes prospectus in connection with the fully guaranteed preferential rights issue of approximately SEK 150 million

    Regulatory press release

    GOTHENBURG, Sweden, May 14, 2020 - Isofol Medical AB’s (publ) (Nasdaq First North Premier Growth…

  • Isofol’s Board of Directors resolve on a fully guaranteed preferential rights issue of approximately SEK 150 million

    Regulatory press release

    GOTHENBURG, Sweden, May 7, 2020 - Isofol Medical AB’s (publ) (Nasdaq First North Premier Growth…

  • Arfolitixorin is presented as one of the most promising pipeline drugs in the new CRC report by Global Data

    News

    Global Data recently published an outlook for the CRC market between 2018 and 2028 for…

  • Isofol’s drug candidate arfolitixorin receives additional clinical patent approval in the United States

    Regulatory press release

    GOTHENBURG, Sweden, May 5, 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth…

  • Information in relation to COVID-19

    Non regulatory press release

    GOTHENBURG, Sweden, April 2, 2020 - Isofol Medical AB (publ), (Nasdaq First North Premier Growth…

  • Isofol announces its intention to carry out a fully guaranteed preferential rights issue of approximately SEK 150 million and a potential over-allotment option of up to approximately SEK 30 million

    Regulatory press release

    GOTHENBURG, Sweden, March 30, 2020 - Isofol Medical AB (publ), (Nasdaq First North Premier Growth…

  • Gene expression data from new analysis method supports that a larger proportion of patients will benefit from arfolitixorin

    Non regulatory press release

    GOTHENBURG, Sweden, March 30, 2020 - Isofol Medical AB (publ), (Nasdaq First North Premier Growth…

  • The first patient included in Japan in Isofol’s Phase 3 AGENT study

    Non regulatory press release

    GOTHENBURG, Sweden, February 18 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL)…

  • Empowered patient podcast

    News

    Our CEO, Dr. Ulf Jungnelius, was featured on Karen Jagoda’s empowered patient podcast to discuss…

  • Gene expression analysis method has been validated by a commercial laboratory

    Non regulatory press release

    GOTHENBURG, Sweden, January 30, 2020 – Isofol Medical AB (publ) (Nasdaq First North Premier: ISOFOL),…

  • Over 200 patients now randomized in the Global Phase 3 AGENT Study

    Non regulatory press release

    GOTHENBURG, Sweden, January 30, 2020 – Isofol Medical AB (publ) (Nasdaq First North Premier: ISOFOL),…

  • The Phase 1/2a study ISO-CC-005 is completed

    Non regulatory press release

    GOTHENBURG, Sweden, January 30, 2020 – Isofol Medical AB (publ) (Nasdaq First North Premier: ISOFOL),…

  • Presentation and poster at ASCO Gastrointestinal Cancers Symposium

    News

    Isofol is attending the event and will present details in the ongoing global Phase 3…

  • The first patient included in Australia in Isofol’s Phase 3 AGENT study

    Non regulatory press release

    GOTHENBURG, Sweden, January 24 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL)…

  • Patent approved in Japan for Isofol’s drug candidate arfolitixorin

    Regulatory press release

    GOTHENBURG, Sweden, December 20, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL).…

  • Patent detecting how patients respond to folate-based cancer treatment approved in the USA

    Regulatory press release

    GOTHENBURG, Sweden, December 13, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),…

  • Isofol to Expand Global Phase 3 AGENT Trial in First-Line Metastatic Colorectal Cancer to Australia

    Non regulatory press release

    GOTHENBURG, Sweden, November 18, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),…

  • Isofol’s board appoints Dr. Jarl Ulf Jungnelius as new CEO of the company

    Regulatory press release

    GOTHENBURG, Sweden, November 13, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),…

  • Pharma’s Almanac – Round table

    News

    Our CEO, Anders Rabbe, was featured twice in Pharma’s Almanac Q3 issue in its “Round…

  • Isofol Receives Positive Feedback from PMDA in Japan, Expanding Ongoing Global Pivotal Phase 3 AGENT Trial in First Line Metastatic Colorectal Cancer

    Non regulatory press release

    GOTHENBURG, Sweden, October 18, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),…

  • Isofol Announces Presentation on the Global Phase 3 Study of arfolitixorin in Metastatic Colorectal Cancer at 2019 ESMO Congress

    Non regulatory press release

    GOTHENBURG, Sweden, September 29, 2019 - Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),…

  • Published abstract at ESMO

    News

    Published abstract at ESMO “Open label phase III study of arfolitixorin vs leucovorin in mFOLFOX-6…

  • Isofol Announces that an Abstract has been Accepted for Presentation at the 2019 ESMO Congress

    Non regulatory press release

    GOTHENBURG, Sweden, September 12, 2019 - Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),…

  • Isofol Announces Management Team Evolution with Appointment of Dr. Roger Tell as Chief Medical Officer

    Non regulatory press release

    GOTHENBURG, Sweden, August 15, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),…

  • Isofol Announces Recent Advisory Board Meeting Covering Development Plan for arfolitixorin

    News

    GOTHENBURG, Sweden, July 15, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),…

  • Isofol Receives Clinical Use Patent Approval in the United States for Drug Candidate arfolitixorin

    Regulatory press release

    GOTHENBURG, Sweden, June 25, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),…

  • Isofol Announces Election of Three New Board Members

    News

    GOTHENBURG, Sweden, June 10, 2019 – Isofol Medical AB (publ) (Nasdaq First North Premier: ISOFOL),…

  • Isofol’s drug candidate arfolitixorin receives clinical patent approval in the United States

    Regulatory press release

    GOTHENBURG, Sweden, May 21, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),…

  • Isofol Reports 58 % Overall Response Rate in Patients with Metastatic Colorectal Cancer in Phase 1/2a Open Label Extension Study with arfolitixorin

    Regulatory press release

    GOTHENBURG, Sweden, May 8, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),…

  • Poadcast – “The Cancer Gene”

    News

    Listen to recent episode from The Cancer Gene podcast features Anders Rabbe, CEO of Isofol,…

  • Isofol Medical AB (publ) appoints Carnegie Investment Bank AB (publ) to Financial advisor

    News

    GOTHENBURG, Sweden, February 27, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),…

  • Isofol Reports All Employees Participate in Newly Created Share Warrant Program

    News

    GOTHENBURG, Sweden, February 1, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),…

  • Isofol has participated in the Empowered Patient Podcast

    Non regulatory press release

    In honor of World Cancer Day on February 4, we would like to share a…

  • Isofol has participated in the Empowered Patient Podcast

    News

    In honor of World Cancer Day on February 4, we would like to share a…

  • Isofol Reports Early Tumor Shrinkage in Patients with Colorectal Cancer in Phase 1/2a Open Label Extension Study with arfolitixorin

    Regulatory press release

    GOTHENBURG, Sweden, January 17, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),…

  • First patient enrolled in Isofol’s Pivotal Phase 3 AGENT study in 1st line metastatic colorectal cancer

    Regulatory press release

    GOTHENBURG, Sweden, December 18, 2018 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL)…

  • Isofol Strengthens Executive Management Team with the Appointment of Roger Tell, MD, PhD, as Chief Scientific Officer and Senior Vice President of Clinical Development

    News

    GOTHENBURG, Sweden, November 19, 2018 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),…

  • Isofol Announces the Appointment of Robert Marchesani as an Advisor to its Board of Directors

    News

    GOTHENBURG, Sweden, November 16, 2018 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),…

  • Isofol Announces the Appointment of Robert Marchesani as an Advisor to its Board of Directors

    News

    GOTHENBURG, Sweden, November 16, 2018 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),…

  • Isofol Announces Initiation of a Pivotal Phase 3 Clinical Trial of arfolitixorin for the Treatment of Metastatic Colorectal Cancer

    Regulatory press release

    GOTHENBURG, Sweden, November 15, 2018 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL)…

  • Isofol presents a poster at ESMO 2018 Congress in Germany

    News

    Isofol is attending the ESMO 2018 Congress in Germany, which is taking place between October…

  • New Chairman and extended board at Isofol Medical AB (publ)

    Regulatory press release

    Isofol Medical AB (publ), developing arfolitixorin as treatment for advanced colorectal cancer is calling an…

  • Patent approved in the United States for Isofol’s drug candidate arfolitixorin

    News

    The patent now approved in the United States expires in 2037 and covers both the…

  • Patent approved in the United States for Isofol’s drug candidate arfolitixorin

    Regulatory press release

    The patent now approved in the United States expires in 2037 and covers both the…

  • DNB initiates monitoring of Isofol

    News

    The Norwegian Bank (DNB) has initiate the monitoring of Isofol Medical AB.     For…

  • Redeye and Isofol are inviting to the live broadcast of pre-ASCO on May 28th

    News

    In connection to this year’s major cancer congress ASCO (American Society of Clinical Oncology) in…

  • Redeye and Isofol are inviting to the live broadcast of pre-ASCO on May 28th

    News

    In connection to this year's major cancer congress ASCO (American Society of Clinical Oncology (https://www.asco.org/)) in…

  • Isofol announces that an abstract with new research resultshas been published for this year’s ASCO congress in Chicago

    Regulatory press release

    Isofol Medical AB (publ) announces that a scientific abstract has been published for this year's…

  • Isofol reports FDAs feedback from the ongoing special protocol assessment (SPA) process

    Regulatory press release

    In March 2018, Isofol Medical AB (publ) submitted a Special Protocol Assessment (SPA) to the…

  • Isofol announces that an abstract describing a genetic prediction of treatment response in CRC treatment to be unveiled at ASCO 2018

    Non regulatory press release

    Isofol Medical AB (publ) announces that an abstract describing correlation between expression levels of folate-related…

  • Invitation to a specialist investor event focusing on late-stage drugs for colorectal cancer with Redeye and Isofol Medical

    News

    On April 10th, Redeye will organize an investor specialist event focusing on late-stage drugs aimed…

  • Isofol Medical has selected arfolitixorin-dose for the phase III pivotal study ISO-CC-007

    Regulatory press release

    The selected dose for the drug candidate arfolitixorin of 120 mg/m2, (approximately 200 mg for…

  • Isofol Medical adopts the World Health Organization recommended name (INN) arfolitixorin for Modufolin®

    Non regulatory press release

    Isofol Medical AB (publ) today announce that the company will in the future be adopting…

  • Isofol reports successful outcome from the scientific advice with the EMA

    Regulatory press release

    Isofol Medical AB (publ) has received positive feedback in scientific advice from the European Medicines…

  • Isofol’s CEO, directors and employees converts stock – and employee options and subscribe shares for SEK 7 655 136

    Non regulatory press release

    The incentive program consisting of stock – and employee options in Isofol Medical AB, which…

  • Positive treatment results with Modufolin® (arfolitixorin) will be published at a cancer congress (ASCO) in the US

    Regulatory press release

    Prior to this year’s Gastrointestinal (GI) Cancers Symposium of the American Society of Clinical Oncology…

  • Successful End-of-Phase 2 meeting with FDA and Phase 3 Program for Modufolin® agreed

    Regulatory press release

    Isofol Medical AB (publ), developing Modufolin®(arfolitixorin) as treatment for advanced colorectal cancer, has had a…

  • Isofol reports positive efficacy data for Modufolin® (arfolitixorin) from patients treated for metastatic colorectal cancer

    Regulatory press release

    Isofol Medical AB (publ), a clinical oncology company, reports efficacy data for Modufolin® (arfolitixorin) from…

  • Isofol to present at the 10th Annual Biotech Showcase Conference

    News

    January 4 2017 Isofol Medical AB (publ), a clinical oncology company, announces that Chief Executive…

  • Isofol to present at the 10th Annual Biotech Showcase Conference

    Non regulatory press release

    Isofol Medical AB (publ), a clinical oncology company, announces that Chief Executive Officer Anders Rabbe…

  • Isofol attends the French-Swedish Life Science Day 2017

    News

    The French-Swedish Life Science Day 2017 conference gathers highly innovative biotech companies from Sweden, French…

  • Isofol announces that an abstract regarding Modufolins® efficacy in colorectal cancer treatment will be presented at ASCO-GI 2018

    News

    Isofol Medical AB (publ) announces that an abstract regarding Modufolins® efficacy in colorectal cancer treatment…

  • ­­­Isofol appoints Gustaf Albèrt as Chief Financial Officer

    Regulatory press release

    Isofol Medical AB (publ) has recruited Gustaf Albèrt as Chief Financial Officer. With extensive experience…

  • Isofol announces that Modufolin® as a rescue therapy in the treatment of osteosarcoma in children is safe and preventive of HDMTX toxicities

    Regulatory press release

    Isofol Medical AB (publ) announces that results from the clinical ISO-MTX-003 study suggest that Modufolin®…

  • Isofol Medical announces successful Type C meeting with FDA regarding its drug candidate, Modufolin® for treatment of metastatic colorectal cancer

    Regulatory press release

    Isofol Medical AB (publ) announces the completion of a successful Type-C meeting with the FDA…

  • From the ongoing ISO-CC-005 study, Isofol reports initial indications of efficacy of Modufolin® in patients with metastatic colorectal cancer

    Regulatory press release

    Isofol Medical AB (publ), a clinical oncology company, announces that the initial indications of Modufolin®…

  • Isofols appoints Sven Erickson as Chief Commercial Officer

    Non regulatory press release

    In preparation for partnering negotiations with pharma companies Isofol Medical AB (publ) announces the appointment…

  • Isofol establish cooperation with Prof. Sten Nilsson and Dr. Alain Herrera in preparation for the upcoming pivotal trial with Modufolin®

    Non regulatory press release

    Isofol Medical AB (publ) announces that Professor Sten Nilsson, an experienced industry advisor and principal…

  • Isofol announces that an abstract about Modufolin® in osteosarcoma treatment will be presented at ESMO 2017

    Non regulatory press release

    Isofol Medical AB (publ) announces that an abstract about Modufolin® has been accepted to be…

  • Scrip Intelligence, a leading source of news and strategic analysis for the global pharmaceutical industry, publish article about Isofol Medical

    Non regulatory press release

    John Davis, journalist and editor for more than 30 years, of Scrip Intelligence recently interviewed…

  • Isofol has enrolled and dosed its first group of patients in the IND-study ISO-FF-001

    Non regulatory press release

    Isofol Medical AB (publ) announced today that the first six patients were enrolled and dosed…

  • New scientific findings strengthen rationale and motivation for Isofol Medical to conduct the pivotal ISO-CC-007 study

    Regulatory press release

    Isofol Medical AB (publ) announced today that academic researchers collaborating with Isofol have presented results…

  • Isofol has initiated five additional study sites in the ISO-CC-005 study in which Modufolin® is evaluated in colorectal cancer

    News

    Isofol Medical AB (publ) announced today that the last one of five additional study sites…

  • Isofol has initiated five additional study sites in the ISO-CC-005 study in which Modufolin® is evaluated in colorectal cancer

    Non regulatory press release

    Isofol Medical AB (publ) announced today that the last one of five additional study sites…

  • Isofol Announces Publication of an Abstract for the 2017 ASCO Annual Meeting

    News

    Isofol Medical AB (publ) announces publication of an abstract regarding failure rate of standard rescue…

  • Isofol Announces Publication of an Abstract for the 2017 ASCO Annual Meeting

    Non regulatory press release

    Isofol Medical AB (publ) announces publication of an abstract regarding failure rate of standard rescue…

  • Pareto Securities has notified Isofol Medical AB that stabilisation measures regarding the Company’s shares have been taken

    Regulatory press release

     In connection with the offering to acquire newly issued shares in Isofol and the listing…

  • Isofol accepted for presentation of abstract at the 2017 ASCO annual meeting

    News

    Isofol Medical AB (publ) announces that an abstract has been accepted to be presented at…

  • Isofol accepted for presentation of abstract at the 2017 ASCO annual meeting

    Non regulatory press release

    Isofol Medical AB (publ) announces that an abstract has been accepted to be presented at…

  • Pareto Securities has notified Isofol Medical AB (publ) that stabilisation measures regarding the Company’s shares have been taken

    Regulatory press release

    In connection with the offering to acquire newly issued shares in Isofol and the listing…

  • Pareto Securities has notified Isofol Medical AB that stabilisation measures regarding the Company’s shares have been taken

    Regulatory press release

    For a complete press release follow the link http://isofol.se/en/ipo/  For additional information, please contact: Anders Rabbe, Managing…

  • Isofol has successfully completed the ISO-MTX-003 study in which Modufolin® is evaluated as rescue therapy

    Non regulatory press release

    Isofol Medical AB announced today that the study ISO-MTX-003 evaluating Modufolin® as rescue therapy (after…

  • Isofol’s largest shareholder and co-founder acquires shares in the company

    Non regulatory press release

    Isofol Medical AB (publ) announces today that its largest shareholder and co-founder, Bengt Gustavsson, now…

  • Isofol’s Chairman of the Board acquires shares in the company

    Non regulatory press release

    Isofol Medical AB (publ) announces that its Chairman of the Board, Jan-Eric Österlund, now acquired…

  • Invitation: Isofol will present it’s contemplated IPO in Stockholm on March 29

    News

    In connection with the contemplated IPO of Isofol Medical on Nasdaq First North Premier, we…

  • Invitation: Isofol will present it’s contemplated IPO in Göteborg on March 22

    News

    In connection with the contemplated IPO of Isofol Medical on Nasdaq First North Premier, we…

  • ISOFOLS BOKSLUTSKOMMUNIKÉ JANUARI – DECEMBER 2016

    News

    Read more here –>

  • ISOFOL ANNOUNCES ITS INTENTION TO LIST ON NASDAQ FIRST NORTH PREMIER

    News

    For a complete press release follow the link https://isofolmedical.com/ipo For additional information, please contact: Anders…

  • ISOFOL ANSÖKER OM VIKTIGT PATENT I USA

    News

    Isofol Medical AB (publ) meddelar att en ny patentansökan lämnats in, den 14 februari, 2017,…

  • EXTRA BOLAGSSTÄMMA I ISOFOL MEDICAL AB

    News

    Aktieägarna i Isofol Medical AB (publ) kallas härmed till extra bolagsstämma onsdagen den 22 februari…

  • SCRIP INTELLIGENCE, A LEADING SOURCE OF NEWS AND STRATEGIC ANALYSIS FOR THE GLOBAL PHARMACEUTICAL INDUSTRY, PUBLISH ARTICLE ABOUT ISOFOL MEDICAL AB’S LEAD CANDIDATE MODUFOLIN®, AND THE UPCOMING PIVOTAL PHASE III STUDY IN METASTATIC COLORECTAL CANCER

    News

    John Davis, journalist and editor for more than 30 years, of Scrip Intelligence recently interviewed…

  • Stockholm Corporate Finance Life Science Day 2015

    News

    Isofol’s Chief Scientific Officer, Anders Vedin presented at the Stockholm Corporate Finance Life Science Day…

  • Stort intresse för göteborgsk life science

    News

    (Swedish) Pressklipp Kemivärlden Biotech / Chemicalnet Behandling av alkoholberoende, cancerläkemedel som testas på patienter och…

  • Isofol tests new medicine against cancer

    News

    (Swedish) Pressklipp Dagens Industri –  Isofol testar ny medicin mot cancer I början av januari…